Clinical Trials Browser

Phase 1/2 × Adenocarcinoma × Cetuximab × Clear all

NCT00716456 2015-04-30

Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib

Phase 1/2 Completed

21 enrolled 8 charts

Adenocarcinoma of Lung, Adenocarcinoma, Lung Neoplasms